Novartis' RLX030 Granted Breakthrough Therapy Designation For Heart Failure RTT News Healthcare products major Novartis International AG (NVS: Quote) said that the US Food and Drug Administration or FDA has granted Breakthrough Therapy designation status to RLX030 or serelaxin, an investigational treatment for patients with acute heart ... |
